---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-089558"
form_type: "8-K"
ticker: null
cik: "0001621227"
company_name: "Adaptimmune Therapeutics PLC"
filed_at: "2025-09-12T23:59:59+00:00"
generated_at: "2026-05-17T06:44:52.641359+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Adaptimmune receives Nasdaq delisting notice for MVLS below $35M; 180-day cure period

## Summary
- Nasdaq notified Adaptimmune on Sept 11, 2025 that MVLS was below $35M minimum for 32 consecutive business days.
- Company also fails alternative continued listing standards: equity below $2.5M or net income below $500K.
- Has 180 calendar days (until March 10, 2026) to regain MVLS compliance for at least 10 consecutive business days.
- No immediate effect on ADAP ADS trading; failure to comply may result in delisting with appeal option.

## SEC filing metadata
- accession: 0001104659-25-089558
- form_type: 8-K
- cik: 0001621227
- company_name: Adaptimmune Therapeutics PLC
- filed_at: 2025-09-12T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 3.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1621227/000110465925089558/0001104659-25-089558-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1621227/000110465925089558/adap-20250911x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-089558
- JSON: https://secwatch.observer/filing/0001104659-25-089558.json
- Plain text: https://secwatch.observer/filing/0001104659-25-089558.txt

## Key facts
- Listing & Compliance Notices
  Adaptimmune Therapeutics PLC received a nasdaq deficiency notice notice regarding other (rules 5550(b)(2)).
  - Exchange: nasdaq
  - Notice: deficiency notice
  - Rules: 5550(b)(2)
  source text: September 11, 2025, Adaptimmune Therapeutics plc (the “Company”) received a written notice (the “Notice”) from the Listing Qualifications Staff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that for the last 32 consecutive business days prior to the date of the Notice, the Company’s Market Value of Listed Securities (“MVLS”) was less than the $35.0 million minimum required for continued listing on The Nasdaq Capital Market, as required by Nasdaq Listing Rule 5550(b)(2) (the “MVLS Listing Rule”). Additionally, as of the date of the Notice, the Company did not mee
  evidence_url: https://www.sec.gov/Archives/edgar/data/1621227/000110465925089558/0001104659-25-089558-index.htm
- Listing & Compliance Notices
  Adaptimmune Therapeutics PLC received a nasdaq deficiency notice notice regarding market value (rules 5550(b)(2)).
  - Exchange: nasdaq
  - Notice: deficiency notice
  - Deficiency: market value
  - Rules: 5550(b)(2)
  source text: September 11, 2025, Adaptimmune Therapeutics plc (the “Company”) received a written notice (the “Notice”) from the Listing Qualifications Staff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that for the last 32 consecutive business days prior to the date of the Notice, the Company’s Market Value of Listed Securities (“MVLS”) was less than the $35.0 million minimum required for continued listing on The Nasdaq Capital Market, as required by Nasdaq Listing Rule 5550(b)(2) (the “MVLS Listing Rule”). Additionally, as of the date of the Notice, the Company did not mee
  evidence_url: https://www.sec.gov/Archives/edgar/data/1621227/000110465925089558/0001104659-25-089558-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.